Nurix Therapeutics, Inc. (NRIX)

NASDAQ • Healthcare

$26.14

+$0.82 (+3.2%)

Market closed

Last close at September 4, 2026 at 20:00 UTC

Day Range$24.98 - $26.22

Avg. Volume (3M)1.1M

Market Cap$2.7B

52 Week Range

$8.2$28.23

Next EarningsIn 34 daysOct 8, 2026

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$9M100%

Gross Profitminus cost of goods$5.1M57%

Fundamentals & Financials

Revenue (TTM)

$36.7M

Net Income (TTM)

-$341.3M

EPS (TTM)

-$3.45

ROA (TTM)

-63.74%

Current Ratio

6.34

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

+26.8%Q3 2025-$0.52

-22.6%Q4 2025-$1.03

+2.4%Q1 2026-$0.82

-3.9%Q2 2026-$0.79

-12.1%Q3 2026-$0.81

Oct 8

in 34 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Miss -12.1%

Nurix Therapeutics’ EPS trailed consensus in the second fiscal quarter of 2026, reported July 9, as revenue fell 79.5% to about $9.0 million from about $44.1 million a year ago. EPS of -$0.81 trailed the -$0.72 estimate, -12%, and compared with -$0.52 a year ago, while gross margin held near 57% and the company posted an operating loss of about $94.2 million. Net loss came to about $89.5 million, down 106.0% from about $43.5 million a year ago, and consensus for the next period calls for EPS of -$0.56 on revenue of $22.5 million.

View full earnings history

About Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc. develops cancer and immunology medicines as a biotechnology company listed on NASDAQ under NRIX, centered on discovering, developing, and commercializing small molecule therapies and antibody therapies for cancer, inflammatory conditions, and other diseases. The business generated $84.0 million of revenue in FY2025.

Name

Nurix Therapeutics, Inc.

CEO

Arthur T. Sands

Website

www.nurixtx.com

Industry

Healthcare

Year Founded

2009

Employees

317

Today's Snapshot

AI-generated

The day ended with NRIX 3.2% higher at 26.14, outperforming a weaker sector.

Trading Volume

Below 10d avg (1.2M)

1.1M

vs S&P 500 Today

Strong Outperformance

+3.66%

Updated: September 4, 2026 at 20:05 UTC

Technical Indicators

5 Buy3 Neutral0 Sell

NRIX presents a strong-buy consensus grounded in a reinforcing medium-term trend while short-term momentum shows caution. ADX around 27 signals a firm trend, and the stock's price near 26 is holding above most longer-term averages even as it sits slightly under the very short SMA and EMA. Momentum and MACD are muted and RSI is neutral, suggesting limited immediate thrust, while ATR shows moderate volatility near 4.0%. Notably the classic pivot sits below the market and supports the bias, although on-balance volume is not confirming the advance. Technical takeaway: strong buy backed by trend and longer moving averages, tempered by weak volume and short-term softness.

All signals